The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the potential mechanisms
Current Opinion in Pharmacology, ISSN: 1471-4892, Vol: 69, Page: 102355
2023
- 27Citations
- 26Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations27
- Citation Indexes27
- 27
- Captures26
- Readers26
- 26
- Mentions1
- News Mentions1
- 1
Most Recent News
Findings on Proglucagon Reported by Investigators at University of Sao Paulo (The Blood Pressure Lowering Effects of Glucagon-like Peptide-1 Receptor Agonists: a Mini-review of the Mechanisms)
2023 APR 21 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Hematology Daily -- Investigators publish new report on Peptide Proteins - Proglucagon.
Review Description
The incretin hormone glucagon-like peptide 1 (GLP-1) is a key component of the signaling mechanisms promoting glucose homeostasis. Clinical and experimental studies demonstrated that GLP-1 receptor agonists, including GLP-1 itself, have favorable effects on blood pressure and reduce the risk of major cardiovascular events, independently of their effect on glycemic control. GLP-1 receptors are present in the hypothalamus and brainstem, the carotid body, the vasculature, and the kidneys. These organs are involved in blood pressure regulation, have their function altered in hypertension, and are positively benefited by the treatment with GLP-1 receptor agonists. Here, we discuss the potential mechanisms whereby activation of GLP-1R signaling exerts blood pressure-lowering effects beyond glycemic control.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1471489223000085; http://dx.doi.org/10.1016/j.coph.2023.102355; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85149779755&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/36857807; https://linkinghub.elsevier.com/retrieve/pii/S1471489223000085; https://dx.doi.org/10.1016/j.coph.2023.102355
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know